المؤلفون: Малика, АДИЛХАНОВА, Раъно, АКРАМОВА

المصدر: 2(5), 68-72, (2024-10-05)

مصطلحات موضوعية: непереносимость лактозы, производство молочных продуктов, лактоза, ферментация, мембранное разделение, обогащение, пищевая ценность, сенсорные свойства

Relation: https://zenodo.org/communities/imfaktorpages; https://doi.org/10.5281/zenodo.13892436; https://doi.org/10.5281/zenodo.13892437; oai:zenodo.org:13892437

الاتاحة: https://doi.org/10.5281/zenodo.13892437

المؤلفون: N. N. Tsyba, A. G. Turkina, Н. Н. Цыба, А. Г. Туркина

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2024); 99-104 ; Медицинский Совет; № 10 (2024); 99-104 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: индивидуализация терапии, tyrosine kinase 2 inhibitors, goals of therapy, intolerance, resistance, rational use, individualization of therapy, ингибиторы тирозинкиназ 2, цели терапии, непереносимость, резистентность, рациональное использование

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8400/7391; Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and giemsa staining. Nature. 1973;243(5405):290–293. https://doi.org/10.1038/243290a0.; Maru Y, Witte ON. The BCR gene encodes a novel serine-threonine kinase activity within a single exon. Cell. 1991;67(3):459–468. https://doi.org/10.1016/0092-8674(91)90521-y.; Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054–1061. https://doi.org/10.1038/leu.2009.38.; Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Lett. 2007;249(2):121–132. https://doi.org/10.1016/j.canlet.2006.07.010.; Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphiapositive patients: by the GIMEMA working party on chronic myeloid leukemia. Clin Cancer Res. 2006;12(24):7374–7379. https://doi.org/10.1158/1078-0432.CCR-06-1516.; Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA. 2002;99(16):10700–10705. https://doi.org/10.1073/pnas.162140299.; Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate – binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102(1):276–283. https://doi.org/10.1182/blood-2002-09-2896.; Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to secondor third-line tyrosine kinase inhibitors. Blood. 2009;114(10):2168–2171. https://doi.org/10.1182/blood-2009-01-197186.; Jabbour E, Kantarjian H, Jones D, Breeden M, Garcia-Manero G, O’Brien S et al. Characteristics and outcomes of patients with сhronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood. 2008;112(1):53–55. https://doi.org/10.1182/blood-2007-11-123950.; Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–874. https://doi.org/10.1182/blood-2013-05-501569.; Туркина АГ, Челышева ЕЮ. Стратегия терапии хронического миелолейкоза: возможности и перспективы. Терапевтический архив. 2013;85(7):4–9. Режим доступа: https://ter-arkhiv.ru/0040-3660/article/view/31271.; Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG et al. Nilotinib in imatinib-resistant or imatinib-intolerant patientswith chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013;27(1):107–112. https://doi.org/10.1038/leu.2012.181.; Shah NP, Rousselot P, Rea D, Cortes JE, Milone J et al. Dasatinib in imatinibresistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016;91(9):869–874. https://doi.org/10.1002/ajh.24423.; Gambacorti-Passerini C, Brümmendorf TH, Kim DW, Turkina AG, Masszi T, Assouline S et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up. Am J Hematol. 2014;89(7):732–742. https://doi.org/10.1002/ajh.23728.; Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012;119(5):1123–1129. https://doi.org/10.1182/blood-2011-08-376087.; Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim D-W et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231–237. https://doi.org/10.1200/JCO.2017.74.7162.; Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648–1671. https://doi.org/10.1038/leu.2016.104.; Cortes J Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naıve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;34(20):2333–2341. https://doi.org/10.1200/JCO.2015.64.8899.; Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T et al. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011;117(8):e75–e87. https://doi.org/10.1182/blood-2010-07-294330.; Mita A, Abumiya M, Miura M, Niioka T, Takahashi S, Yoshioka T et al. Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia. Exp Hematol Oncol. 2018;7:9. https://doi.org/10.1186/s40164-018-0101-1.; Cortes J. How to manage CML patients with comorbidities. Blood. 2020;136(22):2507–2512. https://doi.org/10.1182/blood.2020006911.; Chow EJ, Doody DR, Wilkes JJ, Becker LK, Chennupati S, Morin PE et al. Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees. Leuk Lymphoma. 2021;62(5):1203–1210. https://doi.org/10.1080/10428194.2020.1855340.; Busque L, Harnois M, Szuber N, Delage R, Mollica L, Olney H et al. S159: québec cml research group analysis of treatment patterns in chronic myelogenous leukemia: switching is driven by intolerance and similar across tyrosine kinase inhibitors and lines of treatment. HemaSphere. 2022;6:60–61. https://doi.org/10.1097/01.HS9.0000843528.26169.66; Cortes JE, Lipton JH, Kota V, Castagnetti F, Assouline S, Brümmendorf TH et al. Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study. Hematologica. 2023;108(12):3454–3459. https://doi.org/10.3324/haematol.2022.281944.; Khoury HJ, Goldberg SL, Mauro MJ, Stone RM, Deininger MW, Bradley-Garelik MB et al. Cross-intolerance with dasatinib among imatinib-intolerant patients with chronic phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2016;16(6):341–349. https://doi.org/10.1016/j.clml.2016.03.004.; Lauseker M, Hehlmann R, Hochhaus A, Saußele S. Survival with chronic myeloid leukaemia after failing milestones. Leukemia. 2023;37(11):2231–2236. https://doi.org/10.1038/s41375-023-02028-2.; Kantarjian H. What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia. Leukemia. 2023;37(11):2324–2325. https://doi.org/10.1038/s41375-023-02053-1.; Gener-Ricos G, Haddad FG, Sasaki K, Skinner J, Masarova L, Borthakur G et al. Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results. Clin Lymphoma Myeloma Leuk. 2023;23(10):742–748. https://doi.org/10.1016/j.clml.2023.05.009.; Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S et al. Lowdose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis. Am J Hematol. 2022;97(11):1413–1418. https://doi.org/10.1002/ajh.26689.; Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S et al. Lowdose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021;8(12):e902–911. https://doi.org/10.1016/S2352-3026(21)00333-1.; Brummendorf TH, Gambacorti-Passerini C, Hochhaus A, Lipton JH, Kota V, Deininger MW et al. Efficacy and safety following dose reduction of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia: analysis of the phase 3 BFORE trial. Blood. 2018;132(Suppl. 1):3005. https://doi.org/10.1182/blood-2018-99-110543.; Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol. 2017;4(7):e310–316. https://doi.org/10.1016/S2352-3026(17)30066-2.; Claudiani S, Apperley JF, Szydlo R, Khan A, Nesr G, Hayden C et al. TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia. Br J Haematol. 2021;193(2):346–355. https://doi.org/10.1111/bjh.17286.; Cortes JE, Apperley JF, DeAngelo DJ, Deininger MW, Kota VK et al. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol. 2018;11(1):143. https://doi.org/10.1186/s13045-018-0685-2.; Chen Y, Liu Z, Zou J, Wang D, He W, Meng L, Cheng F et al. Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China. Haematologica. 2022;107(8):1966–1970. https://doi.org/10.3324/haematol.2022.280637.; Isfort S, Manz K, Teichmann LL, Crysandt M, Burchert A, Hochhaus A et al. Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the BosutinibDose Optimization (BODO) Study. Ann Hematol. 2023;102(10):2741–2752. https://doi.org/10.1007/s00277-023-05394-0.; Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim D-W, Issaragrisil S et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–1054. https://doi.org/10.1038/leu.2016.5.; Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R et al. Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(9):1108–1135. https://doi.org/10.6004/jnccn.2018.0071.; Hochhaus A, Saussele S, Rosti G, Mahon F-X, Janssen JJWM, Hjorth-Hansen H et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl. 4):iv261. https://doi.org/10.1093/annonc/mdy159.; Hijiya N, Suttorp M. How I treat chronic myeloid leukemia in children and adolescents. Blood. 2019;133(22):2374–2384. https://doi.org/10.1182/blood.2018882233.; Cortes J, Rea D, Lipton JH. Treatment-free remission with firstand secondgeneration tyrosine kinase inhibitors. Am J Hematol. 2019;94(3):346–357. https://doi.org/10.1002/ajh.25342.; Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M et al. Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica. 2019;104(8):1589–1596. https://doi.org/10.3324/haematol.2018.205054.; Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. https://doi.org/10.1038/s41375-020-0776-2.; Hochhaus A, Breccia M, Saglio G, García-Gutiérrez V, Réa D, Janssen J, Apperley J. Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia.2020;34:1495–1502. https://doi.org/10.1038/s41375-020-0842-9.; Ursan ID, Jiang R, Pickard EM, Lee TA, Ng D, Pickard AS. Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors. J Manag Care Spec Pharm. 2015;21(2):114–122. https://doi.org/10.18553/jmcp.2015.21.2.114.; Khorashad JS, de Lavallade H, Apperley JF, Milojkovic D, Reid AG et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol. 2008;26(29):4806–4813. https://doi.org/10.1200/JCO.2008.16.9953.; Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2022;15(1):113. https://doi.org/10.1186/s13045-022-01334-z.; Ломаиа ЕГ, Шуваев ВА, Читанава ТВ, Матвиенко ЮД, Мартынкевич ИС, Волошин СВ и др. Предикторы эффективности третьей линии терапии ингибиторами тирозинкиназ у пациентов с хронической фазой хронического миелоидного лейкоза: результаты многоцентрового исследования. Клиническая онкогематология. 2022;15(3):271–281. https://doi.org/10.21320/2500-2139-2022-15-3-271-281.; https://www.med-sovet.pro/jour/article/view/8400

الاتاحة: https://www.med-sovet.pro/jour/article/view/8400
https://doi.org/10.21518/ms2024-222

المؤلفون: F. Kh. Orakova, I. K. Tkhabisimova, A. B. Khadzugov, R. A. Ligidova, K. Z. Kodzokova, Z. A. Mizieva, R. M. Alborova, M. R. Khazhkasimov, M. V. Makhmaeva, A. I. Vadaeva, Ф. Х. Оракова, И. К. Тхабисимова, А. Б. Хадзугов, Р. А. Лигидова, К. З. Кодзокова, Ж. А. Мизиева, Р. М. Альборова, М. Р. Хажкасимов, М. В. Махмаева, А. И. Вадаева

المصدر: Meditsinskiy sovet = Medical Council; № 6 (2024); 180-186 ; Медицинский Совет; № 6 (2024); 180-186 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: синкопальные состояния, orthostatic intolerance, postural tachycardia syndrome, orthostatic test, heart rate variability, syncopal conditions, ортостатическая непереносимость, синдром постуральной тахикардии, ортостатическая проба, вариабельность сердечного ритма

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8283/7304; Жиенбаева БС, Мажирова ТБ. Пароксизмальные состояния у взрослых. Вестник КазНМУ. 2021;(3):269–271. https://doi.org/10.53065/kaznmu.2021.91.15.051.; Freeman R, Wieling W, Axelrod F, Benditt D, Benarroch E, Biaggioni I. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Autonom Res. 2011;21(2):69–72. https://doi.org/10.1007/s10286-011-0119-5.; Garland EM, Celedonio JE, Raj SR. Postural tachycardia syndrome: beyond orthostatic intolerance. Curr Neurol Neurosci Rep. 2015;15(9):60. https://doi.org/10.1007/s11910-015-0583-8.; Martone A, Parrini I, Ciciarello F., Galluzzo V, Cacciatore S, Massaro C et al. Recent advances and future directions in syncope management: A comprehensive narrative review. J Clin Med. 2024;13(3):727. https://doi.org/10.3390/jcm13030727.; Vernino S, Bourne K, Stiles L., Grubb BP, Fedorowski A, Stewart JM et al. Postural orthostatic tachycardia syndrome (POTS): state of the science and clinical care from a 2019. National Institutes of Health expert consensus meeting – part 1. Auton Neurosci. 2021;235:102828. https://doi.org/10.1016/j.autneu.2021.102828.; Головина ГА, Сысуенкова ЕВ, Глухова ВЛ, Дупляков ДВ. Динамика вариабельности ритма сердца в ходе тилт-теста у пациентов с вазовагальными синкопами. Функциональная диагностика. 2009;(1):8–13. https://studylib.ru/doc/3744845.; Лебедев ДС, Михайлов ЕН, Неминущий НМ, Голухова ЕЗ, Бабокин ВЕ, Березницкая ВВ и др. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4600. https://doi.org/10.15829/1560-4071-2021-4600.; Гвоздева ЮР, Кантимирова ЕА, Дмитренко ДВ. Проблемы диагностики синдрома постуральной ортостатической тахикардии. Клинические примеры. Доктор. Ру. 2023;22(2):26–31. https://doi.org/10.31550/1727-2378-2023-22-2-26-31.; Kardangusheva A, Tkhabisimova I, Budnik A, Shogenova I, Sizhazheva SKh. Estimation of the cardiovascular morbidity in the population of the KabardinoBalkarian Republic according to the number of visits to health care offices. Cardiometry. 2020;(17):121–126. Available at: https://cardiometry.net/issues/no17-november-2020/cardiovascular-morbidity.; Певзнер АВ, Зюзина НЕ, Хеймец ГИ, Рогоза АН. Дифференциальная диагностика вазовагального обморока, ортостатической гипотонии и барорефлекторной недостаточности у больной с синкопальными состояниями. Кардиология. 2018;58(5):91–96. https://doi.org/10.18087/cardio.2018.5.10126.; Петрова НН, Семенова НВ. Транзиторные потери сознания как междисциплинарная проблема диагностики. Обозрение психиатрии и медицинской психологии имени В.М. Бехтерева. 2023;57(3):30–40. https://doi.org/10.31363/2313-7053-2023-812.; Brignole M, Moya A, Lange F, Deharo JC, Elliott PM, Fanciulli A et al. 2018 ESC Guidelines for the diagnosis and management of syncope. The Task Force for the diagnosis and management of syncope of the (ESC). Developed with the special contribution of the (EHRA). Eur Heart J. 2018;39(21):1883–1948. https://doi.org/10.1093/eurheartj/ehy037.; Shen W, Sheldon R, Benditt D, Cohen MI, Forman DE, Goldberger ZD et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2017;136(5):60–122. https://doi.org/10.1161/CIR.499.; Solbiati M, Casazza G, Dipaola F, Rusconi A, Cernuschi G, Barbic F et al. Syncope recurrence and mortality: a systematicreview. Europace. 2015;17(2):300–308. https://doi.org/10.1093/europace/euu327.; Рогоза АН, Певзнер АВ, Трипотень МИ. Длительная пассивная ортопроба при нейрокардиогенном синкопе. В: Диагностика и лечение нарушений регуляции сердечно-сосудистой системы: материалы IV научно-практической конференции. М.: Медасс; 2002. 361 с.; Arnold A, Ng J, Raj S. Postural tachycardia syndrome – diagnosis, physiology, and prognosis. Auton Neurosci. 2018;215:3–11. https://doi.org/10.1016/j.autneu.2018.02.005.; Diehl R. Continuous progression of orthostatic tachycardia as a futher feature of the postural tachycardia syndrome. Pacing Clin Electrophysiol. 2005;28(9):975–979. https://doi.org/10.1111/j.1540-8159.2005.00215.x.; Taub PR, Zadourian A, Lo HC, Ormiston CK, Golshan S, Hsu JC. Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. J Am Coll Cardiol. 2021;77(7):861–871. https://doi.org/10.1016/j.jacc.2020.12.029.; Школенко ТМ, Школьникова МА. Показания к проведению тилт-теста у детей с нарушением функции синусового узла и с синкопальными состояниями. Вестник аритмологии. 2011;65(65):39–44. Режим доступа: https://vestar.elpub.ru/jour/article/view/529.; Brignole M, Moya A, de Lange FJ, Deharo J, Elliott PМ, Fanciulli A et al. Рекомендации ЕОК по диагностике и лечению синкопальных состояний 2018. Российский кардиологический журнал. 2019;(7):130–194. https://doi.org/10.15829/1560-4071-2019-7-130-194.; AbdelRazek M, Low Ph, Rocca W, Singer W. Epidemiology of postural tachycardia syndrome. Neurology. 2019;92(15). https://doi.org/10.1212/WNL.92.15_supplement.S18.005.; Johansson M, Stahberg M, Runold M, Nygren-Bonnier M, Nilsson J, Olshansky B et al. Long-Haul Post-COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome: The Swedish Experience. JACC Case Rep. 2021;3(4):573–580. https://doi.org/10.1016/j.jaccas.2021.01.009.; Schondorf R, Low P. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? Neurology.1993;43(1):132. https//doi.org/10.1212/wnl.43.1part_1.132.; Трисветова ЕЛ. Синдром постуральной ортостатической тахикардии, как проявление постковидного синдрома. Рациональная фармакотерапия в кардиологии. 2022;18(2):200–208. https://doi.org/10.20996/1819-6446-2022-04-11.; Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2019;140(8):382–482. https://doi.org/10.1161/CIR.0000000000000628.; Schmidt L, Karabin B, Malone A. Postural Orthostatic Tachycardia Syndrome (POTS): Assess, Diagnose, and Evaluate for POTS Treatment (ADEPT). Integr Med Int. 2017;4(3–4):142–153.; Sheldon S, Blair P, Olshansky B, Shen WK, Calkins H, Brignole M et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12(6):41–63. https://doi.org/10.1016/j.hrthm.2015.03.029.; https://www.med-sovet.pro/jour/article/view/8283

الاتاحة: https://www.med-sovet.pro/jour/article/view/8283
https://doi.org/10.21518/ms2024-153

المؤلفون: Дмитрий Валерьевич Гращенков, Алексей Владимирович Вернер

المصدر: Ползуновский вестник, Iss 3, Pp 142–149-142–149 (2023)

مصطلحات موضوعية: рацон питания детей, непереносимость лактозы, пищевые аллергии, разработка блюд методом проектирования, Technology

وصف الملف: electronic resource

Relation: https://ojs.altstu.ru/index.php/PolzVest/article/view/383; https://doaj.org/toc/2072-8921

URL الوصول: https://doaj.org/article/cba6af93d2504b34b5a319887387e13b

المؤلفون: Хазраткулова М. И., Каражанова Т.Дж.

مصطلحات موضوعية: β-галактозидаза, продукты гидролиза лактозы, непереносимость лактозы, углеводный обмен

Relation: https://zenodo.org/communities/sai_2181-3337; https://doi.org/10.5281/zenodo.8372544; https://doi.org/10.5281/zenodo.8372545; oai:zenodo.org:8372545

الاتاحة: https://doi.org/10.5281/zenodo.8372545

المؤلفون: K. O. Shnaider, M. L. Maximov, V. A. Baranova, A. A. Nekipelova, К. О. Шнайдер, М. Л. Максимов, В. А. Баранова, А. А. Некипелова

المساهمون: The study was performed without external funding, Работа выполнена без спонсорской поддержки

المصدر: Safety and Risk of Pharmacotherapy; Том 11, № 4 (2023); 442-449 ; Безопасность и риск фармакотерапии; Том 11, № 4 (2023); 442-449 ; 2619-1164 ; 2312-7821

مصطلحات موضوعية: непереносимость статинов, hyperlipidaemia, atherosclerosis, PCSK9 inhibitor, statins, low density lipoproteins, LDL, cholesterol, statin intolerance, гиперлипидемия, атеросклероз, ингибитор PCSK9, статины, липопротеиды низкой плотности, холестерин

وصف الملف: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/366/874; https://www.risksafety.ru/jour/article/view/366/979; https://www.risksafety.ru/jour/article/downloadSuppFile/366/384; GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71. https://doi.org/10.1016/S0140-6736(14)61682-2; Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13): 1556–65. https://doi.org/10.1001/jama.295.13.jpc60002; Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078–87. https://doi.org/10.1056/NEJMoa1110874; Serban MC, Colantonio LD, Manthripragada AD, Monda KL, Bittner VA, Banach M, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69(11):1386–95. https://doi.org/10.1016/j.jacc.2016.12.036; Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, et al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol. 2017;2(6):598–607. https://doi.org/10.1001/jamacardio.2017.0747; Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022;16(4):361–75. https://doi.org/10.1016/j.jacl.2022.05.068; Dobkin BH. Underappreciated statin-induced myopathic weakness causes disability. Neurorehabil Neural Repair. 2005;19(3):259–63. https://doi.org/10.1177/1545968305277167; Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics. 2005;15(6):415–21. https://doi.org/10.1097/01213011-200506000-00007; Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014;24(10):1057–66. https://doi.org/10.1016/j.numecd.2014.05.009; Sirtori CR, Mombelli G, Triolo M, Laaksonen R. Clinical response to statins: mechanism(s) of variable activity and adverse effects. Ann Med. 2012;44(5):419–32. https://doi.org/10.3109/07853890.2011.582135; Duman I. Role of pharmacogenetics on response to statins: a genotype-based approach to statin therapy outcome. J Cardiol Ther. 2014;1(6):111–20.; Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res. 1998;83(5):490–500. https://doi.org/10.1161/01.res.83.5.490; Eriksson EK, Agmo Hernández V, Edwards K. Effect of ubiquinone-10 on the stability of biomimetic membranes of relevance for the inner mitochondrial membrane. Biochim Biophys Acta Biomembr. 2018;1860(5):1205–15. https://doi.org/10.1016/j.bbamem.2018.02.015; Xu Z, Huo J, Ding X, Yang M, Li L, Dai J, et al. Coenzyme Q10 improves lipid metabolism and ameliorates obesity by regulating CaMKII-mediated PDE4 inhibition. Sci Rep. 2017;7(1):8253. https://doi.org/10.1038/s41598-017-08899-7; Qu H, Guo M, Chai H, Wang WT, Gao ZY, Shi DZ. Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(19):e009835. https://doi.org/10.1161/JAHA.118.009835; Vladutiu GD, Simmons Z, Isackson PJ, Tarnopolsky M, Peltier WL, Barboi AC, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve. 2006;34(2):153–62. https://doi.org/10.1002/mus.20567; Mohaupt MG, Karas RH, Babiychuk EB, Sanchez-Freire V, Monastyrskaya K, Iyer L, et al. Association between statin-associated myopathy and skeletal muscle damage. CMAJ. 2009;181(1–2):E11–8. https://doi.org/10.1503/cmaj.081785; Vinci P, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Mearelli F, et al. Statin-associated myopathy: emphasis on mechanisms and targeted therapy. Int J Mol Sci. 2021;22(21):11687. https://doi.org/10.3390/ijms222111687; Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA. 2003;100(3):928–33. https://doi.org/10.1073/pnas.0335507100; Leblond F, Seidah NG, Précourt LP, Delvin E, Dominguez M, Levy E. Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2009;296(4):G805–15. https://doi.org/10.1152/ajpgi.90424.2008; Langhi C, Le May C, Gmyr V, Vandewalle B, KerrConte J, Krempf M, et al. PCSK9 is expressed in pancreatic delta cells and does not alter insulin secretion. Biochem Biophys Res Commun. 2009;390(4):1288–93. https://doi.org/10.1016/j.bbrc.2009.10.138; Маляревская ОВ, Намитоков АМ, Кручинова СВ, Космачева ЕД. Ингибиторы PCSK9: роль в снижении сердечно-сосудистой заболеваемости. Южно-Российский журнал терапевтической практики. 2022;3(2):32–40. https://doi.org/10.21886/2712-8156-2022-3-2-32-40; Lagace TA. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol. 2014;25(5):387–93. https://doi.org/10.1097/MOL.0000000000000114; Liberale L, Montecucco F, Camici GG, Dallegri F, Vecchie A, Carbone F, Bonaventura A. Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to reduce cardiovascular inflammation and outcomes. Curr Med Chem. 2017;24(14):1403–16. https://doi.org/10.2174/0929867324666170303123734; Davidson MH. PCSK9 antibodies: a dividend of the genomics revolution. Nat Rev Cardiol. 2013;10(11):618–9. https://doi.org/10.1038/nrcardio.2013.139; Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580–90. https://doi.org/10.1001/jama.2016.3608; Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380(9858):1995–2006. https://doi.org/10.1016/S0140-6736(12)61771-1; Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809–19. https://doi.org/10.1056/NEJMoa1316222; Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107. https://doi.org/10.1056/NEJMoa1801174; Roth EM, Kastelein JJP, Cannon CP, Farnier M, McKenney JM, DiCioccio AT, et al. Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial. J Clin Lipidol. 2020;14(5):707–19. https://doi.org/10.1016/j.jacl.2020.07.009; Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Blom D, Seidah NG, et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role. J Lipid Res. 2016;57(6):1086–96. https://doi.org/10.1194/jlr.P065334; Basiak M, Kosowski M, Cyrnek M, Bułdak Ł, Maligłówka M, Machnik G, Okopień B. Pleiotropic effects of PCSK-9 inhibitors. Int J Mol Sci. 2021;22(6):3144. https://doi.org/10.3390/ijms22063144; https://www.risksafety.ru/jour/article/view/366

الاتاحة: https://www.risksafety.ru/jour/article/view/366
https://doi.org/10.30895/2312-7821-2023-366

المؤلفون: I. A. Mazerkina, T. V. Bukatina, T. V. Aleksandrova, И. А. Мазеркина, Т. М. Букатина, Т. В. Александрова

المساهمون: The study reported in this publication was carried out as part of publicly funded research project No. 056-00052- 23-00 and was supported by the Scientific Centre for Expert Evaluation of Medicinal Products (R&D public accounting No. 121021800098-4)., Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 05600052-23-00 на проведение прикладных научных исследований (номер государственного учета НИР 121021800098-4)

المصدر: Safety and Risk of Pharmacotherapy; Том 11, № 3 (2023); 292-302 ; Безопасность и риск фармакотерапии; Том 11, № 3 (2023); 292-302 ; 2619-1164 ; 2312-7821

مصطلحات موضوعية: безопасность лекарственных средств, dyslipidaemia, atherosclerosis, lipid-lowering therapy, statin intolerance, ezetimibe, low density lipoprotein cholesterol, safety of medicinal products, дислипидемия, атеросклероз, гиполипидемическая терапия, непереносимость статинов, эзетимиб, холестерин липопротеидов низкой плотности

وصف الملف: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/385/880; https://www.risksafety.ru/jour/article/downloadSuppFile/385/418; https://www.risksafety.ru/jour/article/downloadSuppFile/385/422; GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223–49. https://doi.org/10.1016/S0140-6736(20)30752-2; Kjekshus J, Pedersen TR. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1995;76(9):64C–8C. https://doi.org/10.1016/s0002-9149(99)80473-1; Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78. https://doi.org/10.1016/S0140-6736(05)67394-1; Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2(1):47–54. https://doi.org/10.1001/jamacardio.2016.4052; Cholesterol Treatment Trialists’ (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81. https://doi.org/10.1016/S0140-6736(10)61350-5; Ежов МВ, Кухарчук ВВ, Сергиенко ИВ, Алиева АС, Анциферов МБ, Аншелес АА и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. https://doi.org/10.15829/1560-4071-2023-5471; Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455; Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):3168–209. https://doi.org/10.1016/j.jacc.2018.11.002; Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, et al. 2021 Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129–50. https://doi.org/10.1016/j.cjca.2021.03.016; Buettner C, Davis RB, Leveille SG, Mittleman MA, Mukamal KJ. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med. 2008;23(8):1182–6. https://doi.org/10.1007/s11606-008-0636-7; Thompson PD, Panza G, Zaleski A, Taylor B. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–410. https://doi.org/10.1016/j.jacc.2016.02.071; Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients — the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403– 14. https://doi.org/10.1007/s10557-005-5686-z; Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding statin use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15. https://doi.org/10.1016/j.jacl.2012.03.003; Tournadre A. Statins, myalgia, and rhabdomyolysis. Joint Bone Spine. 2020;87(1):37–42. https://doi.org/10.1016/j.jbspin.2019.01.018; Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32(10):1924–9. https://doi.org/10.2337/dc09-0738; Ma T, Tien L, Fang CL, Liou YS, Jong GP. Statins and new-onset diabetes: a retrospective longitudinal cohort study. Clin Ther. 2012;34(9):1977–83. https://doi.org/10.1016/j.clinthera.2012.08.004; Howard JP, Wood FA, Finegold JA, Nowbar AN, Thompson DM, Arnold AD, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol. 2021;78(12):1210–22. https://doi.org/10.1016/j.jacc.2021.07.022; Herrett E, Williamson E, Brack K, Beaumont D, Perkins A, Thayne A, et al.; StatinWISE Trial Group. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ. 2021;372:n135. https://doi.org/10.1136/bmj.n135; Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, et al. ASCOT Investigators. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebocontrolled trial and its non-randomised non-blind extension phase. Lancet. 2017;389(10088):2473–81. https://doi.org/10.1016/S0140-6736(17)31075-9; Moon J, Cohen Sedgh R, Jackevicius CA. Examining the nocebo effect of statins through statin adverse events reported in the food and drug administration adverse event reporting system. Circ Cardiovasc Qual Outcomes. 2021;14(1):e007480. https://doi.org/10.1161/CIRCOUTCOMES.120.007480; Penson PE, Mancini GBJ, Toth PP, Martin SS, Watts GF, Sahebkar A, et al. Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group & International Lipid Expert Panel (ILEP). Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. J Cachexia Sarcopenia Muscle. 2018;9(6):1023–33. https://doi.org/10.1002/jcsm.12344; Леонова М.В. Эффекты ноцебо и друцебо в определении статин-индуцированных мышечных симптомов. Медицинский Совет. 2022;(17):136–42. Leonova MV. Effects of nocebo and drucebo in determining statin-induced muscle symptoms. Medical Council. 2022;(17):136–42 (In Russ.). https://doi.org/10.21518/2079-701X-2022-16-17-136-142; Talic S, Marquina C, Ofori-Asenso R, Petrova M, Liew D, Owen AJ, et al. Persistence and adherence to statin therapy: a retrospective cohort study using the Australian national pharmacy data. Cardiovasc Drugs Ther. 2022;36(5):867–77. https://doi.org/10.1007/s10557-021-07199-7; Wong ND, Young D, Zhao Y, Nguyen H, Caballes J, Khan I, Sanchez RJ. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012. J Clin Lipidol. 2016;10(5):1109–18. https://doi.org/10.1016/j.jacl.2016.06.011; Rezende Macedo do Nascimento RC, Mueller T, Godman B, MacBride Stewart S, Hurding S, de Assis Acurcio F, et al. Real-world evaluation of the impact of statin intensity on adherence and persistence to therapy: a Scottish population-based study. Br J Clin Pharmacol. 2020;86(12):2349–61. https://doi.org/10.1111/bcp.14333; Hagen AN, Ariansen I, Hanssen TA, Lappegård KT, Eggen AE, Løchen ML, et al. Achievements of primary prevention targets in individuals with high risk of cardiovascular disease: an 8-year follow-up of the Tromsø study. Eur Heart J Open. 2022;2(5):oeac061. https://doi.org/10.1093/ehjopen/oeac061; Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014;24(10):1057–66. https://doi.org/10.1016/j.numecd.2014.05.009; Pinkosky SL, Groot PHE, Lalwani ND, Steinberg GR. Targeting ATP-citrate lyase in hyperlipidemia and metabolic disorders. Trends Mol Med. 2017;23(11):1047–63. https://doi.org/10.1016/j.molmed.2017.09.001; Pearce NJ, Yates JW, Berkhout TA, Jackson B, Tew D, Boyd H, et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem J. 1998;334(Pt 1):113–9. https://doi.org/10.1042/bj3340113; Burke AC, Telford DE, Huff MW. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 2019;30(1):1–9. https://doi.org/10.1097/MOL.0000000000000565; Pinkosky SL, Filippov S, Srivastava RA, Hanselman JC, Bradshaw CD, Hurley TR, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54(1):134–51. https://doi.org/10.1194/jlr.M030528; Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353–64. https://doi.org/10.1056/NEJMoa2215024; Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022–32. https://doi.org/10.1056/NEJMoa1803917; Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA. 2019;322(18):1780–8. https://doi.org/10.1001/jama.2019.16585; Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662. https://doi.org/10.1161/JAHA.118.011662; Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195–203. https://doi.org/10.1016/j.atherosclerosis.2018.06.002; Banach M, Duell PB, Gotto AM, Laufs U, Leiter LA, Mancini GBJ, et al. Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiol. 2020;5(10):1124–35. https://doi.org/10.1001/jamacardio.2020.2314; Agarwala A, Quispe R, Goldberg AC, Michos ED. Bempedoic acid for heterozygous familial hypercholesterolemia: from bench to bedside. Drug Des Devel Ther. 2021;15:1955–63. https://doi.org/10.2147/DDDT.S251865; Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Role of bempedoic acid in clinical practice. Cardiovasc Drugs Ther. 2021;35(4):853–64. https://doi.org/10.1007/s10557-021-07147-5; Bays HE, Banach M, Catapano AL, Duell PB, Gotto AM, Laufs U, et al. Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials. J Clin Lipidol. 2020;14(5):649–59.e6. https://doi.org/10.1016/j.jacl.2020.08.009; Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy — European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–22. https://doi.org/10.1093/eurheartj/ehv043; Ray K, Bakris G, Banach M, Catapano A, Duell P, Mancini G, et al. Effect of bempedoic acid on uric acid and gout in 3621 patients with hypercholesterolemia: pooled analyses from phase 3 trials. Eur Heart J. 2020;41(Suppl 2):ehaa946.3001. https://doi.org/10.1093/ehjci/ehaa946.3001; Chou R, Dana T, Blazina I, Daeges M, Jeanne TL. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force. JAMA. 2016;316(19):2008–24. https://doi.org/10.1001/jama.2015.15629; Sun H, Wu Y, Bian H, Yang H, Wang H, Meng X, et al. Function of uric acid transporters and their inhibitors in hyperuricaemia. Front Pharmacol. 2021;12:667753. https://doi.org/10.3389/fphar.2021.667753; Ruscica M, Sirtori CR, Carugo S, Banach M, Corsini A. Bempedoic acid: for whom and when. Curr Atheroscler Rep. 2022;24(10):791–801. https://doi.org/10.1007/s11883-022-01054-2; Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it’s not just about OATP1B1. Clin Pharmacol Ther. 2012;92(5):584–98. https://doi.org/10.1038/clpt.2012.163; Shitara Y. Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. Drug Metab Pharmacokinet. 2011;26(3):220–7. https://doi.org/10.2133/dmpk.DMPK-10-RV-094; Jadhav SB, Crass RL, Chapel S, Kerschnitzki M, Sasiela WJ, Emery MG, et al. Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model. Eur Heart J Cardiovasc Pharmacother. 2022;8(6):578–86. https://doi.org/10.1093/ehjcvp/pvab064; Laakso M, Kuusisto J. Diabetes secondary to treatment with statins. Curr Diab Rep. 2017;17(2):10. https://doi.org/10.1007/s11892-017-0837-8; Шпагина ОВ, Бондаренко ИЗ, Колесникова ГС. Терапия статинами ассоциирована с повышением уровня ИРФ-1 у больных ИБС без сахарного диабета. Проблемы эндокринологии. 2018;64(4):200–7. https://doi.org/10.14341/probl8759; Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577–85. https://doi.org/10.1007/s00125-017-4342-z; Zhao X, Ma X, Luo X, Shi Z, Deng Z, Jin Y, et al. Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2020;21(1):86. https://doi.org/10.1186/s40360-020-00463-w; Lin Y, Parco C, Karathanos A, Krieger T, Schulze V, Chernyak N, et al. Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis. BMJ Open. 2022;12(2):e048893. https://doi.org/10.1136/bmjopen-2021-048893; Sayed A, Shazly O, Slipczuk L, Krittanawong C, Baloch F, Virani SS. The clinical efficacy and safety of bempedoic acid in patients at elevated risk of cardiovascular disease: a meta-analysis of randomized clinical trials. Cardiovasc Drugs Ther. 2023 Jun 1. https://doi.org/10.1007/s10557-023-07474-9; Khan MU, Khan MZ, Munir MB, Balla S, Khan SU. Meta-analysis of the safety and efficacy of bempedoic acid. Am J Cardiol. 2020;131:130–2. https://doi.org/10.1016/j.amjcard.2020.06.028; Di Minno A, Lupoli R, Calcaterra I, Poggio P, Forte F, Spadarella G, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2020;9(15):e016262. https://doi.org/10.1161/jaha.119.016262; Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol. 2016;10(3):556–67. https://doi.org/10.1016/j.jacl.2015.12.025; Gutierrez MJ, Rosenberg NL, Macdougall DE, Hanselman JC, Margulies JR, Strange P, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014;34(3):676–83. https://doi.org/10.1161/atvbaha.113.302677; https://www.risksafety.ru/jour/article/view/385

الاتاحة: https://www.risksafety.ru/jour/article/view/385
https://doi.org/10.30895/2312-7821-2023-11-3-292-302

المؤلفون: I. N. Zakharova, I. V. Berezhnaya, D. K. Dmitrieva, Ya. V. Orobinskaya, И. Н. Захарова, И. В. Бережная, Д. К. Дмитриева, Я. В. Оробинская

المصدر: Meditsinskiy sovet = Medical Council; № 1 (2023); 90-95 ; Медицинский Совет; № 1 (2023); 90-95 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: Kabrita, cow’s milk, cow’s milk protein, food allergy, food intolerance, коровье молоко, белок коровьего молока, пищевая аллергия, пищевая непереносимость

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7381/6582; Danielewicz H. Breastfeeding and Allergy Effect Modified by Genetic, Environmental, Dietary, and Immunological Factors. Nutrients. 2022;14(15):3011. https://doi.org/10.3390/nu14153011.; Sakihara T., Otsuji K., Arakaki Y., Hamada K., Sugiura S., Ito K. Randomized trial of early infant formula introduction to prevent cow’s milk allergy. J Allergy Clin Immunol. 2021;147(1):224–232.e8. https://doi.org/10.1016/j.jaci.2020.08.021.; Halken S., Muraro A., de Silva D., Khaleva E., Angier E., Arasi S. et al. EAACI guideline: Preventing the development of food allergy in infants and young children (2020 update). Pediatr Allergy Immunol. 2021;32(5):843–858. https://doi.org/10.1111/pai.13496.; Nanishi K., Hongo H., Tada K. Does giving infant formula to prevent cow’s milk allergy hinder breast-feeding? J Allergy Clin Immunol. 2021;147(3):1118. https://doi.org/10.1016/j.jaci.2020.11.021.; Arasi S., Cafarotti A., Fiocchi A. Cow’s milk allergy. Curr Opin Allergy Clin Immunol. 2022;22(3):181–187. https://doi.org/10.1097/ACI.0000000000000823.; Fiocchi A., Brozek J., Schünemann H., Bahna S.L., von Berg A., Beyer K. et al. World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow’s Milk Allergy (DRACMA) Guidelines. Pediatr Allergy Immunol. 2010;21(Suppl. 21):1–125. https://doi.org/10.1111/j.1399-3038.2010.01068.x.; Fiocchi A., Barrio-Torres J., Dupont C., Howells H.E., Shamir R., Venter C., Meyer R. Hydrolyzed rice formula for dietary management of infants with cow’s milk allergy. World Allergy Organ J. 2022;15(12):100717. https://doi.org/10.1016/j.waojou.2022.100717.; D’Auria E., Salvatore S., Acunzo M., Peroni D., Pendezza E., Di Profio E. et al. Hydrolysed Formulas in the Management of Cow’s Milk Allergy: New Insights, Pitfalls and Tips. Nutrients. 2021;13(8):2762. https://doi.org/10.3390/nu13082762.; Blackham R.J. Goat’s milk for infants. Br Med J. 1906;2(2382):452–453. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2382067/.; Elvehjem C.A. What is new in the nutritive value of milk. J Dairy Sci. 1953;36:1264–1266. https://doi.org/10.3168/jds.S0022-0302(53)91629-4.; Inglingstad R.A., Devold T.G., Eriksen E.K., Holm H., Jacobsen M., Liland K. et al. Comparison of the digestion of caseins and whey proteins in equine, bovine, caprine and human milks by human gastrointestinal enzymes. Dairy Sci Technol. 2010;90:549–563. https://doi.org/10.1051/dst/2010018.; Dalgleish D.G., Spagnuolo P.A., Goff H.D. A possible structure of the casein micelle based on high-resolution field-emission scanning electron microscopy. Int Dairy J. 2004;14(12):1025–1031. https://doi.org/10.1016/j.idairyj.2004.04.008.; Гурова М.М. Смеси на основе козьего молока. Кому, зачем, как. Медицинский совет. 2022;(1):128–133. https://doi.org/10.21518/2079-701X-2022-16-1-128-133.; Jianqin S., Leiming X., Lu X., Yelland G.W., Ni J., Clarke A.J. Effects of milk containing only A2 beta casein versus milk containing both A1 and A2 beta casein proteins on gastrointestinal physiology, symptoms of discomfort, and cognitive behavior of people with self-reported intolerance to traditional cows’ milk. Nutr J. 2016;15:35. https://doi.org/10.1186/s12937-016-0147-z.; Боровик Т.Э., Семенова Н.Н., Лукоянова О.Л., Звонкова Н.Г., Бушуева Т.В., Степанова Т.Н. и др. Эффективность использования адаптированной смеси на основе козьего молока в питании здоровых детей первого полугодия жизни: результаты многоцентрового проспективного сравнительного исследования. Вопросы современной педиатрии. 2017;16(3):226–233. https://doi.org/10.15690/vsp.v16i3.1733.; Wang L., Bravo-Ruiseco G., Happe R., He T., van Dijl J.M., Harmsen H.J.M. The effect of calcium palmitate on bacteria associated with infant gut microbiota. Microbiologyopen. 2021;10(3):e1187. https://doi.org/10.1002/mbo3.1187.; Donovan S.M., Comstock S.S. Human Milk Oligosaccharides Influence Neonatal Mucosal and Systemic Immunity. Ann Nutr Metab. 2016;69(Suppl. 2):42–51. https://doi.org/10.1159/000452818.; Verduci E., D’Elios S., Cerrato L., Comberiati P., Calvani M., Palazzo S. et al. Cow’s Milk Substitutes for Children: Nutritional Aspects of Milk from Different Mammalian Species, Special Formula and Plant-Based Beverages. Nutrients. 2019;11(8):1739. https://doi.org/10.3390/nu11081739.; https://www.med-sovet.pro/jour/article/view/7381

الاتاحة: https://www.med-sovet.pro/jour/article/view/7381
https://doi.org/10.21518/ms2023-036

المؤلفون: O. G. Sivkov, I. N. Leiderman, A. O. Sivkov, A. A. Kolchanov, G. D. Bashlykov, О. Г. Сивков, И. Н. Лейдерман, А. О. Сивков, А. А. Колчанов, Г. Д. Башлыков

المصدر: Messenger of ANESTHESIOLOGY AND RESUSCITATION; Том 19, № 3 (2022); 55-65 ; Вестник анестезиологии и реаниматологии; Том 19, № 3 (2022); 55-65 ; 2541-8653 ; 2078-5658

مصطلحات موضوعية: ацетаминофен, enteral nutrition feeding, feeding intolerance, gastric sonography, acetaminophen, энтеральное питание, непереносимость питания, сонография желудка

وصف الملف: application/pdf

Relation: https://www.vair-journal.com/jour/article/view/674/569; Ревишвили А. Ш., Кубышкин В. А., Затевахин И. И. Острый панкреатит: Клинические рекомендации и др. – Москва: Министерство здравоохранения РФ, 2020. – 66 с.; Сивков О. Г. Прогнозирование возможности питания в тонкую кишку у пациентов с распространенным вторичным перитонитом // Общая реаниматология. – 2021. – Т. 17, № 1. – С. 27‒33. doi 10.15360/1813-9779-2021-1-27-33.; Сивков О. Г., Лейдерман И. Н., Луцюк М. И. Прогнозирование непереносимости энтерального питания у пациентов в критическом состоянии // Вестник интенсивной терапии им. А. И. Салтанова. – 2020. – № 4. – С. 120‒126. doi 10.21320/1818-474X-2020-4-120-126.; Agarwala R., Rana S. S., Sharma R. et al. gastrointestinal failure is a predictor of poor outcome in patients with acute pancreatitis // Dig. Dis. Sci. – 2020. – Vol. 65, № 8. – P. 2419‒2426. doi:10.1007/s10620-019-05952-5. Epub 2019 Nov 13. PMID: 31722056.; Banks P. A., Bollen T. L., Dervenis C. et al. Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus // Gut. – 2013. – Vol. 62, № 1. – P. 102‒111. doi:10.1136/gutjnl-2012-302779. Epub 2012 Oct 25. PMID: 23100216.; Blaser A. R., Starkopf J., Kirsimägi Ü. et al. Definition, prevalence, and outcome of feeding intolerance in intensive care: a systematic review and meta-analysis // Acta Anaesthesiol. Scand. – 2014. – Vol. 58, № 8. – P. 914‒922. doi:10.1111/aas.12302. Epub 2014 Mar 11. PMID: 24611520.; Dutta A. K., Goel A., Kirubakaran R. et al. Nasogastric versus nasojejunal tube feeding for severe acute pancreatitis // Cochrane Database Syst Rev. – 2020. – Vol. 26, № 3. – CD010582. doi:10.1002/14651858.CD010582.pub2.; Fan H., Yang C., Duan Z. et al. Risk factors of enteral feeding intolerance in severe acute pancreatitis patients: A protocol for systematic review and meta-analysis // Medicine (Baltimore). – 2021. – Vol. 7, № 100. – Р. e25614. doi:10.1097/MD.0000000000025614.; Gao T., Cheng M. H., Xi F. C. et al. Predictive value of transabdominal intestinal sonography in critically ill patients: a prospective observational study // Crit Care. – 2019. – Vol. 27, № 23 (1). – P. 378. doi:10.1186/s13054-019-2645-9. PMID: 31775838; PMCID: PMC6880579.; Hamada S. R., Garcon P., Ronot M. et al. Ultrasound assessment of gastric volume in critically ill patients // Int. Care Med. – 2014. – Vol. 40, № 7. – P. 965‒972. doi:10.1007/s00134-014-3320-x.; Heyland D., Cook D. J., Winder B. et al. Enteral nutrition in the critically ill patient: a prospective survey // Crit. Care Med. – 1995. – Vol. 23, № 6. – P. 1055‒1060. doi:10.1097/00003246-199506000-00010.; Hu B., Sun R., Wu A. et al. Severity of acute gastrointestinal injury grade is a predictor of all-cause mortality in critically ill patients: a multicenter, prospective, observational study // Crit. Care. – 2017. – Vol. 14, № 21 (1). – P. 188. doi:10.1186/s13054-017-1780-4.; Hurt R. T., McClave S. A. Gastric residual volumes in critical illness: what do they really mean? // Crit. Care Clin. – 2010. – Vol. 26, № 3. – P. 481‒490. doi:10.1016/j.ccc.2010.04.010. PMID: 20643301.; Liu Y., Gao Y. K., Yao L. et al. Modified B-ultrasound method for measurement of antral section only to assess gastric function and guide enteral nutrition in critically ill patients // World J Gastroenterol. – 2017. – Vol. 28, № 23. – P. 5229‒5236. doi:10.3748/wjg.v23.i28.5229.; Marzio L., Giacobbe A., Conoscitore P. et al. Evaluation of the use of ultrasonography in the study of liquid gastric emptying // Am. J. Gastroenterol. – 1989. – Vol. 84, № 5. – P. 496‒500. PMID: 2655434.; McClave S. A., Gualdoni J., Nagengast A. et al. Gastrointestinal dysfunction and feeding intolerance in critical illness: do we need an objective scoring system? // Curr Gastroenterol Rep. – 2020. – Vol. 7, №22. doi:10.1007/s11894-019-0736-z. PMID: 31912312.; McClave S. A., Taylor B. E., Martindale R. G. et al. Society of Critical Care Medicine; American Society for Parenteral and Enteral Nutrition. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) // J. Parenter. Enteral. Nutr. – 2016. – Vol. 40, № 2. – P. 159‒211. doi:10.1177/0148607115621863.; Miyauchi T., Ishikawa M., Tashiro S. et al. Acetaminophen absorption test as a marker of small bowel transplant rejection // Transplantation. – 1997. – Vol. 27, № 8. – P. 1179‒1182. doi:10.1097/00007890-199704270-00020.; Nguyen T., Frenette A. J., Johanson C. et al. Impaired gastrointestinal transit and its associated morbidity in the intensive care unit // J. Crit. Care. – 2013. – Vol. 28, № 4. – P. 537. – e11-7. doi:10.1016/j.jcrc.2012.12.003.; Pan L. L., Li J. Shamoon M. et al. Recent Advances on nutrition in treatment of acute pancreatitis // Front Immunol. – 2017. – Vol. 30, № 8. – P. 762. doi:10.3389/fimmu.2017.00762.; Perez-Calatayud A. A., Carrillo-Esper R., Anica-Malagon E. D. et al. Point-of-care gastrointestinal and urinary tract sonography in daily evaluation of gastrointestinal dysfunction in critically ill patients (GUTS Protocol) // Anaesthesiol. Int. Ther. – 2018. – Vol. 50, № 1. – P. 40‒48. doi:10.5603/AIT.a2017.0073.; Puleo F., Arvanitakis M., Van Gossum A. et al. Gut failure in the ICU // Semin Respir Crit Care Med. – 2011. – Vol. 32, № 5. – P. 626‒638. doi:10.1055/s-0031-1287871.; Reignier J., Mercier E., Le Gouge A. et al. Clinical Research in Intensive Care and Sepsis (CRICS) Group. Effect of not monitoring residual gastric volume on risk of ventilator-associated pneumonia in adults receiving mechanical ventilation and early enteral feeding: a randomized controlled trial // JAMA. – 2013. – Vol. 16, № 3. – P. 249–256. doi:10.1001/jama.2012.196377. PMID: 23321763.; Reintam A., Jakob S. M., Starkopf J. Gastrointestinal failure in the ICU // Curr. Opin. Crit. Care. – 2016. – Vol. 22, № 2. – P. 128–141. doi:10.1097/MCC.0000000000000286.; Reintam A., Malbrain M. L., Starkopf J. et al. Gastrointestinal function in intensive care patients: terminology, definitions and management. Recommendations of the ESICM Working Group on Abdominal Problems // Int. Care Med. – 2012. – Vol. 38, № 3. – P. 384–394. doi:10.1007/s00134-011-2459-y.; Reintam A., Parm P., Kitus R. et al. Gastrointestinal failure score in critically ill patients: a prospective observational study // Crit Care. – 2008. – Vol. 12, № 4. – R90. doi:10.1186/cc6958.; Singer P., Blaser A. R., Berger M. M. et al. ESPEN guideline on clinical nutrition in the intensive care unit // Clin. Nutr. – 2019. – Vol. 38, № 1. – P. 48–79. doi:10.1016/j.clnu.2018.08.037.; Southren D. L., Nardone A. D., Haastrup A. A. et al. An examination of gastrointestinal absorption using the acetaminophen absorption test in critically ill patients with COVID-19: A retrospective cohort study // Nutr. Clin. Pract. – 2021. – Vol. 36, № 4. – P. 853–862. doi:10.1002/ncp.10687.; Sun J. K., Li W. Q., Ni H. B. et al. Modified gastrointestinal failure score for patients with severe acute pancreatitis // Surg. Today. – 2013. – Vol. 43, № 5. – P. 506–513. doi:10.1007/s00595-013-0496-6.; Tenner S., Baillie J., DeWitt J. et al. American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis // Am. J. Gastroenterol. – 2013. – Vol. 108, № 9. – P. 1400–1416. doi:10.1038/ajg.2013.218.; Tenner S., Steinberg W. M. Acute Pancreatitis. 10th ed. Feldman M., Friedman L. S., Brandt L. J., editors. In: Sleisenger and Fordtran’s gastrointestinal and liver disease // Philadelphia: Elsevier Inc. – 2016. – P. 969–993.; https://www.vair-journal.com/jour/article/view/674

الاتاحة: https://www.vair-journal.com/jour/article/view/674
https://doi.org/10.21292/2078-5658-2022-19-3-55-65

المؤلفون: A. Sivkov O., O. Sivkov G., I. Leiderman N., E. Zaitsev Yu., I. Popov B., А. Сивков О., О. Сивков Г., И. Лейдерман Н., Е. Зайцев Ю., И. Попов Б.

المساهمون: The study had no sponsorship Affiliations, Исследование не имеет спонсорской поддержки

المصدر: Russian Sklifosovsky Journal "Emergency Medical Care"; Том 11, № 1 (2022); 42-49 ; Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь»; Том 11, № 1 (2022); 42-49 ; 2541-8017 ; 2223-9022

مصطلحات موضوعية: acute pancreatitis, enteral nutrition, intolerance, residual, volume, stomach, nausea, vomiting, bloating, nasogastric, nasojejunal, small intestine, острый панкреатит, энтеральное питание, непереносимость, остаточный, объем, желудок, тошнота, рвота, вздутие живота, назогастральное, назоеюнальное, тонкая кишка

وصف الملف: application/pdf

Relation: https://www.jnmp.ru/jour/article/view/1338/1085; Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, et al. Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102–111. https://doi.org/10.1136/gutjnl-2012-302779; Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101(10):2379–2400. PMID: 17032204 https://doi.org/10.1111/j.1572-0241.2006.00856.x; Buter A, Imrie CW, Carter CR, Evans S, McKay CJ. Dynamic nature of early organ dysfunction determines outcome in acute pancreatitis. Br J Surg. 2002;89(3):298–302 PMID: 11872053 https://doi.org/10.1046/j.0007-1323.2001.02025.x; Johnson CD, Abu-Hilal M. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. Gut. 2004;53(9):1340–1344. PMID: 15306596 https://doi.org/10.1136/gut.2004.039883; Petrov MS, van Santvoort HC, Besselink MG, van der Heijden GJ, Windsor JA, Gooszen HG. Enteral nutrition and the risk of mortality and infectious complications in patients with severe acute pancreatitis: A meta-analysis of randomized trials. Arch Surg. 2008;143(11):1111–1117. PMID: 19015471 https://doi.org/10.1001/archsurg.143.11.1111; Dellinger EP, Forsmark CE, Layer P, Lévy P, Maraví-Poma E, Petrov MS, et al. Determinant-based classification of acute pancreatitis severity: An international multidisciplinary consultation. Ann Surg. 2012;256(6):875–880. PMID: 22735715 https://doi.org/10.1097/SLA.0b013e318256f778; Singh N, Sharma B, Sharma M, Sachdev V, Bhardwaj P, Mani K, et al. Evaluation of early enteral feeding through nasogastric and nasojejunal tube in severe acute pancreatitis: a noninferiority randomized controlled trial. Randomized Controlled Trial. 2012;41(1):153–159. PMID: 21775915 https://doi.org/10.1097/MPA.0b013e318221c4a8; Eatock FC, Chong P, Menezes N, Murray L, McKay CJ, Carter CR, et al. A randomized study of early nasogastric versus nasojejunal feeding in severe acute pancreatitis. Am J Gastroenterol. 2005;100(2):432–439. PMID: 15667504 https://doi.org/10.1111/j.1572-0241.2005.40587; Dutta AK, Goel A, Kirubakaran R, Chacko A, Tharyan P. Nasogastric versus nasojejunal tube feeding for severe acute pancreatitis. Cochrane Database Syst Rev. 2020;3(3):CD010582. PMID: 32216139 https://doi.org/10.1002/14651858.CD010582.pub2; Bevan MG, Asrani V, Petrov MS. The oral refeeding trilemma of acute pancreatitis: what, when and who? Expert Rev Gastroenterol Hepatol. 2015;9(10):1305–1312 PMID: 26289104 https://doi.org/10.1586/17474124.2015.1079125; Li H, Yang Z, Tian F. Risk factors associated with intolerance to enteral nutrition in moderately severe acute pancreatitis: A retrospective study of 568 patients. Saudi J Gastroenterol. 2019;25(6):362–368. PMID: 30900608 https://doi.org/10.4103/sjg.SJG_550_18; Bevan MG, Asrani VM, Bharmal S, Wu LM, Windsor JA, Petrov MS. Incidence and predictors of oral feeding intolerance in acute pancreatitis: A systematic review, meta-analysis, and meta-regression. Clin Nutr. 2017;36(3):722–729. PMID: 27346178 https://doi.org/10.1016/j.clnu.2016.06.006; Tenner S, Baillie J, DeWitt J, Vege SS. American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(9):1400–1415; 1416. PMID: 23896955 https://doi.org/10.1038/ajg.2013.218; Reintam Blaser A, Malbrain ML, Starkopf J, Fruhwald S, Jakob SM, De Waele J, et al. Gastrointestinal function in intensive care patients: terminology, definitions and management. Recommendations of the ESICM Working Group on Abdominal Problems. Intensive Care Med. 2012;38(3):384–394. PMID: 22310869 https://doi.org/10.1007/s00134-011-2459-y; Hoffmann M, Schwarz CM, Fürst S, Starchl C, Lobmeyr E, Sendlhofer G, et al. Risks in Management of Enteral Nutrition in Intensive Care Units: A Literature Review and Narrative Synthesis. Nutrients. 2020;13(1):82. PMID: 33383941 https://doi.org/10.3390/nu13010082; Gungabissoon U, Hacquoil K, Bains C, Irizarry M, Dukes G, Williamson R, et al. Prevalence, risk factors, clinical consequences, and treatment of enteral feed intolerance during critical illness. JPEN J Parenter Enteral Nutr. 2015;39(4):441–448. PMID: 24637246 https://doi.org/10.1177/0148607114526450; Hsu CW, Sun SF, Lee DL, Lin SL, Wong KF, Huang HH, et al. Impact of disease severity on gastric residual volume in critical patients. World J Gastroenterol. 2011;17(15):2007–2012. PMID: 21528080 https://doi.org/10.3748/wjg.v17.i15.2007; Edes TE, Walk BE, Austin JL. Diarrhea in tube-fed patients: feeding formula not necessarily the cause. Am J Med. 1990;88(2):91–93. PMID: 2105646 https://doi.org/10.1016/0002-9343(90)90454-l; Montejo JC. Enteral nutrition-related gastrointestinal complications in critically ill patients: a multicenter study. Crit Care Med. 1999;27(8):1447–1453. PMID: 10470748 https://doi.org/10.1097/00003246-199908000-00006; Catafesta J, Francesconi C. Association between medication use and adverse gastroenterologic events in patients receiving enteral nutrition therapy at a University Hospital. Rev Gastroenterol Mexico. 2012;77(4):161–166. PMID: 23142405 https://doi.org/10.1016/j.rgmx.2012.06.003; Wesselink E, Koekkoek KWAC, Looijen M, van Blokland DA, Witkamp RF, van Zanten ARH. Associations of hyperosmolar medications administered via nasogastric or nasoduodenal tubes and feeding adequacy, food intolerance and gastrointestinal complications amongst critically ill patients: A retrospective study. Clin Nutr ESPEN. 2018;25:78–86. PMID: 29779822 https://doi.org/10.1016/j.clnesp.2018.04.001; Wei X, Day AG, Ouellette-Kuntz H, Heyland DK. The association between nutritional adequacy and long-term outcomes in critically ill patients requiring prolonged mechanical ventilation. Crit Care Med. 2015;43:1569–1579. PMID: 25855901 https://doi.org/10.1097/CCM.0000000000001000; Alberda C, Gramlich L, Jones N, Jeejeebhoy K, Day AG, Dhaliwal R, et al. The relationship between nutritional intake and clinical outcomes in critically ill patients: results of an international multicenter observational study. Intensive Care Med. 2009;35(10):1728–1737. PMID: 19572118 https://doi.org/10.1007/s00134-009-1567-4; Marik PE, Hooper MH. Normocaloric versus hypocaloric feeding on the outcomes of ICU patients: a systematic review and meta-analysis. Intensive Care Med. 2016;42(3):316–323. PMID: 26556615 https://doi.org/10.1007/s00134-015-4131-4; Preiser JC, van Zanten AR, Berger MM, Biolo G, Casaer MP, Doig GS, et al. Metabolic and nutritional support of critically ill patients: consensus and controversies. Crit Care. 2015;19(1):35. PMID: 25886997 https://doi.org/10.1186/s13054-015-0737-8; Arabi YM, Casaer MP, Chapman M, Heyland DK, Ichai C, Marik PE, et al. The intensive care medicine research agenda in nutrition and metabolism. Intensive Care Med. 2017;43(9):1239–1256. PMID: 28374096 https://doi.org/10.1007/s00134-017-4711-6; Huang HH, Chang SJ, Hsu CW, Chang TM, Kang SP, Liu MY. Severity of illness influences the efficacy of enteral feeding route on clinical outcomes in patients with critical illness. J Acad Nutr Diet. 2012;112(8):1138–1146. PMID: 22682883 https://doi.org/10.1016/j.jand.2012.04.013; https://www.jnmp.ru/jour/article/view/1338

الاتاحة: https://www.jnmp.ru/jour/article/view/1338
https://doi.org/10.23934/2223-9022-2022-11-1-42-49

المؤلفون: N. V. Mikryukova, N. M. Kalinina, Н. В. Микрюкова, Н. М. Калинина

المصدر: Medical Immunology (Russia); Том 24, № 1 (2022); 181-186 ; Медицинская иммунология; Том 24, № 1 (2022); 181-186 ; 2313-741X ; 1563-0625

مصطلحات موضوعية: непереносимость гистамина, histamine, diamine oxidase, DAO, histamine intolerance, гистамин, диаминоксидаза, ДАО

وصف الملف: application/pdf

Relation: https://www.mimmun.ru/mimmun/article/view/2204/1511; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2204/7537; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2204/7538; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2204/7539; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2204/7540; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2204/7541; https://www.mimmun.ru/mimmun/article/downloadSuppFile/2204/8822; Boehm T., Pils S., Gludovacz E., Szoelloesi H., Petroczi K., Majdic O., Jilma B. Quantification of human diamine oxidase. Clin. Biochem., 2017, Vol. 50, no. 7-8, pp. 444-451.; Daschner A., González-Fernández J., Valls A., de Frutos C., Rodero M., Cuéllar C. Diamine oxidase levels in different chronic urticaria phenotypes. Allergol. Immunopathol. (Madr.), 2015, Vol. 43, no. 6, pp. 593-600.; Doeun D., Davaatseren M., Chung M.-S. Biogenic amines in foods. Food Sci. Biotechnol., 2017, Vol. 26, no. 6, pp. 1463-1474.; Enko D., Meinitzer A., Mangge H., Kriegshäuser G., Halwachs-Baumann G., Reininghaus E.Z., Schnedl W.J. Concomitant prevalence of low serum diamine oxidase activity and carbohydrate malabsorption. Can. J. Gastroenterol. Hepatol., 2016, 4893501. doi:10.1155/2016/4893501.; Gludovacz E., Maresch D., de Carvalho L.L., Puxbaum V., Baier L.J., Sützl L., Guédez G., Grünwald-Gruber C., Ulm B., Pils S., Ristl R., Altmann F., Jilma B., Salminen T.A., Borth N., Boehm T. Oligomannosidic glycans at asn-110 are essential for secretion of human diamine oxidase. J. Biol. Chem., 2018, Vol. 293, pp. 1070-1087.; Kacik J., Wróblewska B., Lewicki S., Zdanowski R., Kalicki B. Serum diamine oxidase in pseudoallergy in the pediatric population. Adv. Exp. Med. Biol., 2018, Vol. 1039, pp. 35-44.; Kovacova-Hanuskova E., Buday T., Gavliakova S., Plevkova J. Histamine, histamine intoxication and intolerance. Allergol. Immunopathol. (Madr.), 2015, Vol. 43, no. 5, pp. 498-506.; Lackner S., Malcher V., Enko D., Mangge H., Holasek S.J., Schnedl W.J. Histamine-reduced diet and increase of serum diamine oxidase correlating to diet compliance in histamine intolerance. Eur. J. Clin. Nutr., 2018, Vol. 73, pp. 102-104.; Manzotti G., Breda D., di Gioacchino M., Burastero S.E. Serum diamine oxidase activity in patients with histamine intolerance. Int. J. Immunopathol. Pharmacol., 2016, Vol. 29, pp. 105-111.; Mušič E., Korošec P., Šilar M., Adamič K., Košnik M., Rijavec M. Serum diamine oxidase activity as a diagnostic test for histamine intolerance. Wien. Klin. Wochenschr., 2013, Vol. 125, no. 9-10, pp. 239-243.; Pinzer T.C., Tietz E., Waldmann E., Schink M., Neurath M.F., Zopf Y. Circadian profiling reveals higher histamine plasma levels and lower diamine oxidase serum activities in 24% of patients with suspected histamine intolerance compared to food allergy and controls. Allergy, 2017, Vol. 73, no. 4, pp. 949-957.; Reese I., Ballmer-Weber B., Beyer K., Fuchs T., Kleine-Tebbe J., Klimek L., Worm M. German guideline for the management of adverse reactions to ingested histamine. Allergo J. Int., 2017, Vol. 26, no. 2, pp. 72-79.; Refaat M.M., Abdel-Rehim A.S., Elmahdi A.R., Mohamed N.A., Ghonaim S.S. Diamine oxidase enzyme: a novel biomarker in respiratory allergy. Int. Forum Allergy Rhinol., 2019, Vol. 9, no. 12, pp. 1478-1484.; Schnedl W.J., Schenk M., Lackner S., Enko D., Mangge H., Forster F. Diamine oxidase supplementation improves symptoms in patients with histamine intolerance. Food Sci. Biotechnol., 2019, Vol. 28, pp. 1779-1784.; Skypala I.J., Williams M., Reeves L., Meyer R., Venter C. Sensitivity to food additives, vaso-active amines and salicylates: a review of the evidence. Clin. Transl. Allergy, 2015, Vol. 5, no. 1, 34. doi:10.1186/s13601-015-0078-3.; Smolinska S., Jutel M., Crameri R., O’Mahony L. Histamine and gut mucosal immune regulation. Allergy, 2013, Vol. 69, no. 3, pp. 273-281.; Solymosi D., Sárdy M., Pónyai G. Interdisciplinary significance of food-related adverse reactions in adulthood. Nutrients, 2020, Vol. 12, no. 12, 3725. doi:10.3390/nu12123725.; Son J.H., Chung B.Y., Kim H.O., Park C.W. A histamine-free diet is helpful for treatment of adult patients with chronic spontaneous urticaria. Ann. Dermatol., 2018, Vol. 30, no. 2, pp. 164-172.; Wagner A., Buczyłko K., Zielińska-Bliźniewska H., Wagner W. Impaired resolution of wheals in the skin prick test and low diamine oxidase blood level in allergic patients. Adv. Dermatol. Allergol., 2019, Vol. 36, no. 5, pp. 538-543.; Wagner N., Dirk D., Peveling-Oberhag A., Reese I., Rady-Pizarro U., Mitzel H., Staubach P. A Popular myth – low-histamine diet improves chronic spontaneous urticaria – fact or fiction? J. Eur. Acad. Dermatol. Venereol., 2016, Vol. 31, no. 4, pp. 650-655.; Wollin A., Wang X., Tso P. Nutrients regulate diamine oxidase release from intestinal mucosa. Am. J.Physiol., 1998, Vol. 275, no. 4, pp. R969-R975.; Yacoub M.-R., Ramirez G.A., Berti A., Mercurio G., Breda D., Saporiti N., Colombo G. Diamine oxidase supplementation in chronic spontaneous urticaria: a randomized, double-blind placebo-controlled study. Int. Arch. Allergy Immunol., 2018, Vol. 176, no. 3-4, pp. 268-271.; https://www.mimmun.ru/mimmun/article/view/2204

الاتاحة: https://www.mimmun.ru/mimmun/article/view/2204
https://doi.org/10.15789/1563-0625-ROD-2204

المؤلفون: Чуракова, А. С., Лазарев, В. А., Churakova, A. S., Lazarev, V. A.

مصطلحات موضوعية: РАСТИТЕЛЬНОЕ МОЛОКО, НЕПЕРЕНОСИМОСТЬ ЛАКТОЗЫ, ЗДОРОВОЕ ПИТАНИЕ, PLANT-BASED MILK, LACTOSE INTOLERANCE, HEALTHY EATING

وصف الملف: application/pdf

Relation: Экологическая безопасность в техносферном пространстве : сборник материалов Четвертой Международной научно-практической конференции преподавателей, молодых ученых и студентов. - Екатеринбург, 2021; Чуракова, А. С. «Не молоко» – экологичная альтернатива молоку: преимущества, виды, технология производства / А. С. Чуракова, В. А. Лазарев // Экологическая безопасность в техносферном пространстве : сборник материалов Четвертой Международной научно-практической конференции преподавателей, молодых ученых и студентов (Екатеринбург, 20 мая 2021 г.) / Рос. гос. проф.-пед. ун-т. - Екатеринбург : РГППУ, 2021. - С. 204-209.; https://elar.rsvpu.ru/handle/123456789/36842

الاتاحة: https://elar.rsvpu.ru/handle/123456789/36842

المؤلفون: Sivkov, O. G., Sivkov, A. O., Popov, I. B., Zajcev, E. Ju., Сивков, О. Г., Сивков, А. О., Попов, И. Б., Зайцев, Е. Ю.

مصطلحات موضوعية: ACUTE PANCREATITIS, ENTERAL NUTRITION, INTOLERANCE, GASTRIC RESIDUAL VOLUME, NAUSEA, VOMITING, ABDOMINAL DISTENSION, ОСТРЫЙ ПАНКРЕАТИТ, ЭНТЕРАЛЬНОЕ ПИТАНИЕ, НЕПЕРЕНОСИМОСТЬ, ОСТАТОЧНЫЙ, ОБЪЕМ, ЖЕЛУДОК, ТОШНОТА, РВОТА, ВЗДУТИЕ ЖИВОТА

وصف الملف: application/pdf

Relation: Уральский медицинский журнал. 2021. т. 20. №4; Тяжесть заболевания как фактор риска непереносимости энтерального питания в ранний период острого панкреатита / О. Г. Сивков, А. О. Сивков, И. Б. Попов, Е. Ю. Зайцев. – Текст: электронный // Уральский медицинский журнал. – Екатеринбург: УГМУ, 2021. - т. 20, № 4. - c. 53-59.; http://elib.usma.ru/handle/usma/6314

الاتاحة: http://elib.usma.ru/handle/usma/6314

المؤلفون: Sarkisyan, K. A., Zholudev, S. E., Саркисян, К. А., Жолудев, С. Е.

المصدر: Сборник статей

مصطلحات موضوعية: INTOLERANCE TO CONSTRUCTION MATERIALS, LIGHT-CURING BASE MATERIAL, TOOTH LOSS, НЕПЕРЕНОСИМОСТЬ КОНСТРУКЦИОННЫХ МАТЕРИАЛОВ, СВЕТООТВЕРЖДАЕМЫЙ БАЗИСНЫЙ МАТЕРИАЛ, ЗУБОВ

وصف الملف: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения: Материалы VI Международной научно-практической конференции молодых учёных и студентов, посвященной году науки и технологий, (Екатеринбург, 8-9 апреля 2021): в 3-х т.; Саркисян, К. А. Опыт использования модернизированного фотополимерного базисного материала для изготовления съемных зубных протезов / К. А. Саркисян, С. Е. Жолудев // Актуальные вопросы современной медицинской науки и здравоохранения: материалы VI Международной научно-практической конференции молодых учёных и студентов, посвященной году науки и технологий, (Екатеринбург, 8-9 апреля 2021 г.) : в 3-х т. – Екатеринбург : УГМУ, 2021. – Т.2. – С. 814-818.; http://elib.usma.ru/handle/usma/5916

الاتاحة: http://elib.usma.ru/handle/usma/5916

المؤلفون: Суслікова, Л.В., Сербенюк, А.В., Лоншакова, М.С.

المصدر: Репродуктивне здоров'я жінки; № 5 (2021); 65-71 ; Reproductive health of woman; № 5 (2021); 65-71 ; Reproductive health of woman; No. 5 (2021); 65-71 ; 2708-8731 ; 2708-8723

مصطلحات موضوعية: symptomatic endometriosis, food intolerance, impaired carbohydrate metabolism, gluten, lactose, fructose, autoimmunization, immune system, симптомный эндометриоз, пищевая непереносимость, нарушение углеводного обмена, глютен, лактоза, фруктоза, аутоиммунизация, иммунная система, симптомний ендометріоз, харчова непереносимість, порушення вуглеводного обміну, аутоімунізація, імунна система

وصف الملف: application/pdf

Relation: http://repro-health.com.ua/article/view/240029/241717; http://repro-health.com.ua/article/view/240029

الاتاحة: http://repro-health.com.ua/article/view/240029
https://doi.org/10.30841/2708-8731.5.2021.240029

المؤلفون: O. G. Sivkov, О. Г. Сивков

المصدر: General Reanimatology; Том 17, № 1 (2021); 27-33 ; Общая реаниматология; Том 17, № 1 (2021); 27-33 ; 2411-7110 ; 1813-9779

مصطلحات موضوعية: перитонит, small intestine, acetaminophen absorption test, enteral feeding, nasojejunal feeding, feeding intolerance, critical illness, peritonitis, тонкая кишка, тест абсорбции ацетаминофена, энтеральное питание, назоеюнальное питание, непереносимость питания, критическое состояние

وصف الملف: application/pdf

Relation: https://www.reanimatology.com/rmt/article/view/2012/1477; https://www.reanimatology.com/rmt/article/view/2012/1484; Reintam A., Parm P., Kitus R., Kern H., Starkopf J. Gastrointestinal symptoms in intensive care patients. Acta Anaesthesiol Scand. 2009; 53: 318–324. DOI:10.1111/j.1399-6576.2008.01860.x.; Zhang D., Fu R., Li Y., Li H., Li Y, Li H. Comparison of the clinical characteristics and prognosis of primary versus secondary acute gastrointestinal injury in critically ill patients. J Intensive Care. 2017; 5: 26. Published 2017 Apr 20. DOI:10.1186/s40560-017-0221-4.; Reintam Blaser A., Malbrain, M. L., Starkopf J., Fruhwald S., Jakob S. M., De Waele J., Braun J. P., Poeze M., Spies C. Gastrointestinal function in intensive care patients: terminology, definitions and management. Recommendations of the ESICM Working Group on Abdominal Problems. Intensive Care Med. 2012: 38, 3; 384–394. PMID: 22310869 PMCID: PMC3286505 DOI:10.1007/s00134-011-2459-y; Kar P., Jones K.L., Horowitz M., Chapman M.J., Deane A.M. Measurement of gastric emptying in the critically ill. Clin Nutr. 2015; 34: 557– 564. DOI:10.1016/j.clnu.2014.11.003; Medhus A.W., Lofthus C.M., Bredesen J., Husebye E. Gastric emptying: the validity of the paracetamol absorption test adjusted for individual pharmacokinetics. Neurogastroenterol Motil. 2001; 13: 179–185. PMID: 11437980 DOI:10.1046/j.1365-2982.2001.00249.x; Miyauchi T., Ishikawa M., Tashiro S., Hisaeda H., Nagasawa H., Himeno K. Acetaminophen absorption test as a marker of small bowel transplant rejection. Transplantation. 1997; 63 (8): 1179–1182. DOI:10.1097/00007890-199704270-00020; Kreymann K.G., Berger M.M., Deutz N.E., Hiesmayr M., Jolliet P., Kazandjiev G., Nitenberg G., Berghe G., Wernerman J., Ebner C., Hartl W., Heymann C., Spies C. ESPEN guidelines on enteral nutrition: intensive care. Clin Nutr. 2006; 25: 210–223. DOI:10.1016/j.clnu.2006.01.021.; Vincent J.L., Moreno R., Takala J., Willatts S., De Mendonça A., Bruining H., Reinhart C.K., Suter P.M., Thijs L.G. Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med. 1996; 22 (7): 707–710. PMID: 8844239 DOI:10.1007/BF01709751; Knaus W.A., Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13: 818–829. DOI:10.1097/00003246-198510000-00009; Singer M., Deutschman C.S., Seymour C.W., Shankar-Hari M., Annane D., Bauer M., Bellomo, R., Bernard, G.R., Chiche, J.D., Coopersmith C.M., Hotchkiss R.S., Levy M.M., Marshall J.C., Martin G.S., Opal S.M., Rubenfeld G.D., van der Poll T., Vincent J. L., Angus D.C. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315 (8): 801–810. DOI:10.1001/jama.2016.0287; Reintam A., Parm P., Kitus R., Starkopf J., Kern H. Gastrointestinal failure score in critically ill patients: a prospective observational study [published correction appears in Crit Care. 2008; 12 (6): 435. Crit Care. 2008; 12 (4): R90. DOI:10.1186/cc6958.; Greiff J.M., Rowbotham D. Pharmacokinetic drug interactions with gastrointestinal motility modifying agents. Clin Pharmacokinet. 1994; 27: 447–461. PMID: 7882635 DOI:10.2165/00003088-199427060-00004; Sachdev A.H., Pimentel M. Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Ther Adv Chronic Dis. 2013; 4: 223–231. PMID: 23997926 PMCID: PMC3752184 DOI:10.1177/2040622313496126; McClave S.A., Taylor B.E., Martindale R.G., Warren M.M., Johnson D.R., Braunschweig, C., McCarthy M.S., Davanos E., Rice T.W., Cresci G.A., Gervasio J.M., Sacks G.S., Roberts P.R., Compher C. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) JPEN J Parenter Enteral Nutr. 2016; 40: 159–211. DOI:10.1177/0148607115621863.; Alkhawaja S., Martin C., Butler R.J., Gwadry-Sridhar F. Post-pyloric versus gastric tube feeding for preventing pneumonia and improving nutritional outcomes in critically ill adults. Cochrane Database Syst Rev. 2015; 2015 (8): CD008875. DOI:10.1002/14651858.; Davies A.R., Morrison S.S., Bailey M.J., Bellomo R., Cooper D.J., Doig G.S., Finfer S.R., Heyland D.K. ENTERIC Study Investigators; ANZICS Clinical Trials Group. A multicenter, randomized controlled trial comparing early nasojejunal with nasogastric nutrition in critical illness. Crit Care Med. 2012; 40: 2342–2348. DOI:10.1097/CCM.0b013e318255d87e.; Minard G., Kudsk K A., Melton S., Patton J.H., Tolley E.A. Early versus delayed feeding with an immune-enhancing diet in patients with severe head injuries. J Parenter Enter Nutr. 2000; 24: 145–149. DOI:10.1177/0148607100024003145.; Davies A.R., Froomes P.R., French C.J., Bellomo R., Gutteridge G.A., Nyulasi I., Walker R., Sewell R.B. Randomized comparison of nasojejunal and nasogastric feeding in critically ill patients. Crit Care Med. 2002; 30: 586–590. DOI:10.1097/00003246-200203000-00016.; Hsu C.W., Sun S.F., Lin S.L., Kang S.P., Chu K.A., Lin C.H., Huang H.H. Duodenal versus gastric feeding in medical intensive care unit patients: a prospective, randomized, clinical study. Crit Care Med. 2009; 37: 1866–1872. DOI:10.1097/CCM.0b013e31819ffcda.; Singer P., Blaser A.R., Berger M.M., Alhazzani W., Calder P.C., Casaer M.P., Hiesmayr M., Mayer K., Montejo J.C., Pichard C., Preiser J.-C., van Zanten Arthur R.H., Oczkowski S., Szczeklik W., Bischoff S.C. ESPEN guideline on clinical nutrition in the intensive care unit. Clinical Nutrition. 2019; 38 (1): 48–79. DOI:10.1016/j.clnu.2018.08.037.; Sciarretta G., Furno A., Mazzoni M., Garagnani B., Malaguti P. Lactulose hydrogen breath test in orocecal transit assessment. Critical evaluation by means of scintigraphic method. Dig Dis Sci. 1994; 39: 1505–1510. PMID: 8026263 DOI:10.1007/BF02088056; Madsen J.L., Larsen N.E., Hilsted J., Worning H. Scintigraphic determination of gastrointestinal transit times. A comparison with breath hydrogen and radiologic methods. Scand J Gastroenterol. 1991; 26: 1263–1271. PMID: 1763296 DOI:10.3109/00365529108998623; Rauch S., Krueger K., Turan A., You J., Roewer N., Sessler D.I. Use of wireless motility capsule to determine gastric emptying and small intestinal transit times in critically ill trauma patients. J Crit Care. 2012; 27 (534): e7–e12. PMID: 22300488 DOI:10.1016/j.jcrc.2011.12.002; Gao T., Cheng M.H., Xi F.C., Chen Y., Cao C., Su T., Li W.Q., Yu W.K. Predictive value of transabdominal intestinal sonography in critically ill patients: a prospective observational study. Crit Care. 2019; 23 (1): 378. DOI:10.1186/s13054-019-2645-9. PMID: 31775838; PMCID: PMC6880579.; Zusman O., Theilla M., Cohen J., Kagan I., Bendavid I., Singer P. Resting energy expenditure, calorie and protein consumption in critically ill patients: a retrospective cohort study. Crit Care. 2016; 20 (1): 367. DOI:10.1186/s13054-016-1538-4.; Wang W.N., Yang M.F., Wang C.Y., Hsu C.Y., Lee B.J., Fu P.K. Optimal Time and Target for Evaluating Energy Delivery after Adjuvant Feeding with Small Bowel Enteral Nutrition in Critically Ill Patients at High Nutrition Risk. Nutrients. 2019; 11 (3): 645. Published 2019 Mar 16. DOI:10.3390/nu11030645.; https://www.reanimatology.com/rmt/article/view/2012

الاتاحة: https://www.reanimatology.com/rmt/article/view/2012
https://doi.org/10.15360/1813-9779-2021-1-27-33

المؤلفون: V. O. Kaybysheva, Ye. K. Baranskaya

المصدر: Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 27, Iss 5, Pp 94-104 (2018)

مصطلحات موضوعية: непереносимость углеводов, лактазная недостаточность, гиполактазия взрослых, метеоризм, альфа-галактозидаза, Diseases of the digestive system. Gastroenterology, RC799-869

وصف الملف: electronic resource

Relation: https://www.gastro-j.ru/jour/article/view/185; https://doaj.org/toc/1382-4376; https://doaj.org/toc/2658-6673

URL الوصول: https://doaj.org/article/ad2e1bbe18b44a4f9fa5cae9eb5ca7e0

المؤلفون: T. V. Krasnoselskikh, E. V. Sokolovskiy

المصدر: Vestnik Dermatologii i Venerologii, Vol 0, Iss 2, Pp 23-40 (2017)

مصطلحات موضوعية: сифилис, антибиотикотерапия, пенициллин, нейросифилис, сифилис у беременных, сифилис и вич-инфекция, непереносимость пенициллина, антибиотики резерва, серологическая резистентность, syphilis, antibiotic therapy, penicillin, neurosyphilis, syphilis in pregnancy, syphilis and hiv, penicillin allergy, alternative treatment regimens, serofast state, Dermatology, RL1-803

وصف الملف: electronic resource

Relation: https://www.vestnikdv.ru/jour/article/view/120; https://doaj.org/toc/0042-4609; https://doaj.org/toc/2313-6294

URL الوصول: https://doaj.org/article/61f1b0462c9b4ef59dbb824f6317b658

المؤلفون: Муравьев Ю.В., Тремаскина П.О., Лебедева В.В.

مصطلحات موضوعية: ревматоидный артрит, метотрексат, непереносимость метотрексата, опросник MISS

Relation: https://doi.org/10.5281/zenodo.4066847; https://doi.org/10.5281/zenodo.4066848; oai:zenodo.org:4066848

الاتاحة: https://doi.org/10.5281/zenodo.4066848

المؤلفون: Gontsaryuk, D. O., Ferfetska, K. V., Kuzik, F. V., Pits, L. O.

المصدر: Achievements of Clinical and Experimental Medicine; No. 2 (2019); 175-179 ; Достижения клинической и экспериментальной медицины; № 2 (2019); 175-179 ; Здобутки клінічної і експериментальної медицини; № 2 (2019); 175-179 ; 2415-8836 ; 1811-2471 ; 10.11603/1811-2471.2019.v0.i2

مصطلحات موضوعية: chronic pancreatitis, allergy, urticaria, eczema, food intolerance, bronchospasm, хронический панкреатит, аллергия, крапивница, экзема, пищевая непереносимость, бронхоспазм, хронічний панкреатит, алергія, кропив’янка, екзема, харчова непереносимість

وصف الملف: application/pdf

Relation: https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/10449/9988; https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/10449; https://repository.tdmu.edu.ua//handle/123456789/13988

الاتاحة: https://repository.tdmu.edu.ua//handle/123456789/13988
https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/10449
https://doi.org/10.11603/1811-2471.2019.v0.i2.10449